MARKET

IVVD

IVVD

Invivyd
NASDAQ
4.440
+0.440
+11.00%
After Hours: 4.280 -0.16 -3.60% 17:20 03/28 EDT
OPEN
3.960
PREV CLOSE
4.000
HIGH
4.560
LOW
3.960
VOLUME
1.50M
TURNOVER
0
52 WEEK HIGH
5.20
52 WEEK LOW
0.9802
MARKET CAP
488.91M
P/E (TTM)
-2.8584
1D
5D
1M
3M
1Y
5Y
Invivyd’s Financial Stability Hangs in the Balance as HHS Reviews PEMGARDA’s Emergency Use Authorization
TipRanks · 4h ago
IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023
Invivyd reported earnings per share of -67 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -42 cents. Invivyd also reported no earnings for the third quarter of 2018.
Investorplace · 16h ago
Invivyd: Annual report
Press release · 20h ago
Invivyd: Q4 Earnings Insights
Invivyd reported its Q4 earnings on March 28. Invivyd missed estimated earnings by -60.0%. The company is expected to report earnings of $-0.67 per share. Last quarter the company beat on EPS by $0.14. The company's revenue was down $0 from the same period last year.
Benzinga · 21h ago
Adagio Therapeutics GAAP EPS of -$1.81
Invivyd expects to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024. Cash and cash equivalents were $200.6 million as of December 31, 2023. Adagio Therapeutics reports FY GAAP EPS of -$1.81.
Seeking Alpha · 23h ago
*Invivyd FY23 Net $198.6M >IVVD
Dow Jones · 23h ago
*Invivyd FY23 EPS $1.81 >IVVD
Dow Jones · 23h ago
Press Release: Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights. Received emergency use authorization for PEMGARDA, a monoclonal antibody authorized in the U.S. For pre-exposure prophylaxis of COVID-19 in certain adults and adolescents. Cash and cash equivalents of $200.6 million as of December 31, 2023.
Dow Jones · 23h ago
More
About IVVD
Invivyd, Inc. is a biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases. It delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify antibodies with a barrier to viral escape. It has a robust pipeline of antibody candidates for the prevention and treatment of COVID-19, including VYD222, a novel antibody. VYD222 is a monoclonal antibody candidate that has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5. VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.

Webull offers Invivyd Inc stock information, including NASDAQ: IVVD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IVVD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IVVD stock methods without spending real money on the virtual paper trading platform.